Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects (Q36617012)

15 August 2017

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects (English)

1 reference

adaptive radiation therapy

15 August 2017

0 references

1 reference

R Eeles

5

0 references

author name string

D P Dearnaley

1

1 reference

15 August 2017

E Hall

2

1 reference

15 August 2017

D Lawrence

3

1 reference

15 August 2017

R A Huddart

4

1 reference

15 August 2017

C M Nutting

6

1 reference

15 August 2017

J Gadd

7

1 reference

15 August 2017

A Warrington

8

1 reference

15 August 2017

M Bidmead

9

1 reference

15 August 2017

A Horwich

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

92

1 reference

15 August 2017

3

1 reference

15 August 2017

488-498

1 reference

Radiotherapy and combined modality approaches in localised prostate cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

An evaluation of three-field coplanar plans for conformal radiotherapy of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Portal imaging protocol for radical dose-escalated radiotherapy treatment of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

30 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

30 September 2017

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602301

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Prostate motion during standard radiotherapy as assessed by fiducial markers

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362084

Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602301

Is there more than one late radiation proctitis syndrome?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602301

Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602301

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

21 January 2018

1 reference

12 December 2020

Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era

1 reference

12 December 2020

Toward optimal external-beam fractionation for prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation

1 reference

12 December 2020

A critical evaluation of the planning target volume for 3-D conformal radiotherapy of prostate cancer

1 reference

12 December 2020

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect

1 reference

12 December 2020

Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response

1 reference

12 December 2020

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer

1 reference

12 December 2020

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

12 December 2020

Consensus conference. The management of clinically localized prostate cancer

1 reference

12 December 2020

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

12 December 2020

Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results

1 reference

12 December 2020

What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy

1 reference

12 December 2020

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

12 December 2020

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

12 December 2020

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low

1 reference

12 December 2020

Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI

1 reference

12 December 2020

The required number of treatment imaging days for an effective off-line correction of systematic errors in conformal radiotherapy of prostate cancer--a radiobiological analysis

1 reference

12 December 2020

Late GI and GU complications in the treatment of prostate cancer

1 reference

12 December 2020

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

12 December 2020

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

12 December 2020

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

12 December 2020

A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy

1 reference

12 December 2020

A randomized study of the use of a customized immobilization system in the treatment of prostate cancer with conformal radiotherapy

1 reference

12 December 2020

Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602301

1 reference

release_silubrdwpvas3ljzeljarstgni

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/silubrdwpvas3ljzeljarstgni

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

PubMed publication ID

15685244

1 reference